Compare ONL & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | PMN |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.5M | 115.5M |
| IPO Year | 2021 | 2022 |
| Metric | ONL | PMN |
|---|---|---|
| Price | $2.99 | $10.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 334.5K | 25.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,647,000.00 | N/A |
| Revenue This Year | $4.10 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.86 | $0.29 |
| 52 Week High | $3.04 | $27.40 |
| Indicator | ONL | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 46.21 |
| Support Level | $2.81 | $10.55 |
| Resistance Level | N/A | $13.80 |
| Average True Range (ATR) | 0.10 | 0.50 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 78.26 | 63.84 |
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.